A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs IC 14 (Primary)
  • Indications Motor neuron disease
  • Focus Adverse reactions
  • Sponsors Implicit Bioscience
  • Most Recent Events

    • 06 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top